Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-VRd versus VRd in previously untreated transplant-eligible multiple myeloma
NL-OMON58869Phase 3Active, not recruiting
- Sponsor
- European Myeloma Network B.V.
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of daratumumab, bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by European Myeloma Network B.V. Primary endpoint: Progression-free survival. Started Feb 2019; status: active, not recruiting.
02
Drugs
daratumumabbortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON58869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58869.